# Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

> **NCT04312503** · — · COMPLETED · sponsor: **Aziende Chimiche Riunite Angelini Francesco S.p.A** · enrollment: 95 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Lurasidone
- **DRUG:** aripiprazole, olanzapine, quetiapine or risperidone

## Key facts

- **NCT ID:** NCT04312503
- **Lead sponsor:** Aziende Chimiche Riunite Angelini Francesco S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-13
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04312503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04312503, "Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04312503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*